Posted by Michael Wonder on 18 Mar 2026
FDA approval of Icotyde (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
18 March 2026 - Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favourable safety profile in a once daily pill.
Johnson & Johnson announced today that the US FDA has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and paediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.
